TRUE KnORTH 2: Testing Regional Anesthesia Techniques for Up and Early Discharge Following Knee Arthroplasty

Sponsor
McMaster University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06054750
Collaborator
(none)
226
2
29.9

Study Details

Study Description

Brief Summary

To assess postoperative patient-reported quality of recovery after total knee arthroplasty (TKA) with periarticular joint injection (PAI) ± single shot adductor canal block with or without adductor canal catheter infusion.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

Knee osteoarthritis (KOA) is a leading cause of chronic knee pain and disability, with a lifetime prevalence of 45%. Treatment for symptomatic KOA includes physical therapy, oral anti-inflammatory medications and intra-articular steroid injections, with total knee arthroplasty (TKA) (or knee replacement) as the definitive treatment. Acute postoperative pain is common after TKA, leading to increased opioid consumption and increased hospital length of stay. Pain control following TKA has been investigated with interventions such as intrathecal morphine, nerve blocks, and periarticular joint injection (PAI). PAI and adductor canal block are well-established techniques used both in combination or in isolation in the management of postoperative pain for patients undergoing TKA. The aim of this study is to assess postoperative patient-reported quality of recovery after TKA with PAI and single shot adductor canal block with or without adductor canal catheter infusion.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
226 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized control trialRandomized control trial
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Pharmacy will have access to the randomization scheme. All other members of the study team are blinded.
Primary Purpose:
Treatment
Official Title:
Testing Regional Anesthesia Techniques for Up and Early Discharge Following Knee Arthroplasty: Quality Of Recovery Through Patient Reporting - a Multisite Study
Anticipated Study Start Date :
Jan 1, 2024
Anticipated Primary Completion Date :
Mar 31, 2026
Anticipated Study Completion Date :
Jun 30, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: cACB active

Periarticular joint injection (medication) + single shot adductor canal block (medication) + adductor canal catheter infusion (medication)

Drug: Ropivacaine
800 mg ropivacaine in continuous infusion adductor canal block (400 mL total volume)

Placebo Comparator: cACB sham

Periarticular joint injection (medication) + single shot adductor canal block (medication) + adductor canal catheter infusion (normal saline)

Drug: Normal saline
400 mL normal saline in continuous infusion adductor canal block (400 mL total volume)

Outcome Measures

Primary Outcome Measures

  1. Quality of Recovery-15 Survey scores [Postoperative day 0 (2 hours postoperatively), and morning of postoperative days 1, 2 and 3]

    Patient-reported Quality of Recovery scores, where higher scores indicate better quality of recovery

Secondary Outcome Measures

  1. Quality of Recovery-15 Survey scores [Postoperative days 10 and 42]

    Patient-reported Quality of Recovery scores, where higher scores indicate better quality of recovery

  2. Brief Pain Inventory - Pain Interference scores [Postoperative days 1, 2 and 3 in the morning]

    On a scale of 0-10, where 0=Does not interfere and 10=Completely interferes, Patients will rate how much their pain interferes with: General activity, Mood, Walking ability, Normal work including housework, Relations with other people, Sleep, and Enjoyment of life

  3. Pain Numerical Rating Scale at rest [Postoperative Day 0 (2 hours postoperatively), and morning of postoperative days 1, 2 and 3]

    Patient-reported pain measured on an 11-point scale from 0 [no pain] to 10 [worst pain imaginable]

  4. Pain Numerical Rating Scale with activity [Postoperative Day 0 (2 hours postoperatively), and morning of postoperative days 1, 2 and 3 after physiotherapy]

    Patient-reported pain measured on an 11-point scale from 0 [no pain] to 10 [worst pain imaginable]

  5. Functional Recovery: Range of motion [Postoperative Day 0 (2 hours postoperatively), and morning of postoperative days 1, 2 and 3 after physiotherapy]

    Flexion and Extension range of motion measured in degrees

  6. Functional Recovery: Time to reach discharge criteria [Postoperative Day 0 (2 hours postoperatively), and morning of postoperative days 1, 2 and 3 after physiotherapy]

    Physiotherapist to assess when patient meets discharge criteria (measured in half days)

  7. Functional Recovery: Timed Up and Go test [Postoperative day 42]

    Time it takes for patient to stand up from sitting in a chair, walk 3 meters, then turn and walk back to chair and sit down, measured in seconds

  8. Frequency of opioid-related side effects (vomiting and nausea) [Up to 3 days]

    Number of vomiting events or complaints of nausea noted in nursing notes

  9. Narcotic consumption in hospital [Up to 3 days]

    total amount and route of administration collected from routine and PRN opioid use in PACU and on surgical floor - measured in mg of oral morphine equivalence

  10. Narcotic consumption at home [Postoperative day 42]

    Post-discharge opioid consumption will be tracked with pill count on POD 1 or 2, 3 POD10 (± 2 days), and POD42 (± 2 days); on POD 42 - patient to show study nurse how many pills remain to ensure reporting accuracy

  11. Complications [Postoperative days 10 and 42]

    i. return to hospital once discharged for non-analgesic reasons ii. require more pain medications outside of prescription given

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • All adult patients presenting for a primary TKA.
Exclusion Criteria:
  • Age <18 years;

  • Body mass index ≥45 kg/m2;

  • Weight <80 kg;

  • Deemed unsuitable for regional anesthesia;

  • Planned general anesthesia;

  • Hepatic insufficiency/Intolerance to acetaminophen;

  • Renal insufficiency (defined by estimated glomerular filtration rate <60 mL/min/1.73 m2);

  • Chronic opioid use (individuals requiring the equivalent of 1 mg or more of intravenous morphine, or 3 mg or more of oral morphine per hour for greater than 1 month);

  • Allergy or intolerance to study medications (listed under 'Spinal and Adductor Canal Block') or trial medications listed in "Postoperative" section and "standard prescription"

  • Clinical Frailty Scale score ≥4;

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • McMaster University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
McMaster University
ClinicalTrials.gov Identifier:
NCT06054750
Other Study ID Numbers:
  • TRUE KnORTH 2.0
First Posted:
Sep 26, 2023
Last Update Posted:
Sep 26, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 26, 2023